EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria

L Zubiaga-Fernandez, A Testera-Montes, C Rondon iD, N Perez-Sanchez, F Gomez-Perez, J M Vega-Chicote, J Bartra, M Ferrer iD, I Eguiluz-Gracia iD, M J Torres

Clinical & Experimental Allergy · 2024

DOI: 10.1111/cea.14462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von L Zubiaga-Fernandez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Allergy Unit, Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIO…. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Biomarkers, Anti-Allergic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Novartis Pharmaceuticals Corporation, Consejería de Salud y Bienestar Social, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher doses and/or longer treatment. This study assesses the real‐life performance of OMA in severe CSU and identifies factors associated with the response.

Methods

CSU patients eligible for OMA were recruited prospectively. Clinical data and a blood test were collected before OMA initiation. Urticaria Activity Score 7 (UAS7) was calculated at baseline and every 3 months during OMA treatment. CSU control was defined as UAS7 300 mg/4 weeks. A blood basophil count >20 cells/μL (OR 13.33; 95% CI 3.32–52.63; p < .001) and the absence of hypothyroidism (OR 3.65; 95% CI 0.78–16.95; p = .099) were identified as predictive factors to achieve control with 300 mg/4 weeks. Twelve patients were able to stop OMA during the study (responders in remission, RR). RR had received OMA for a median of 29 months (12–53 months). Conversely, 32 patients had been on OMA for >29 months at the end of the study (active responders, AR). AR had received OMA for a median of 45 months (30–100 months). There were no significant differences in clinical or analytical factors between RR and AR patients.

Conclusions

Low blood basophil count and the presence of hypothyroidism might serve as biomarkers for the controller dose of OMA in severe CSU patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaBiomarkersAnti-Allergic AgentsHumansFemaleMaleAdultMiddle AgedTreatment OutcomeAgedSeverity of Illness IndexYoung AdultProspective StudiesBasophils

Stichwörter der Autor:innen

BIOBADALERblood basophil countchronic spontaneous urticariahypothyroidismomalizumab

Substanzen

OmalizumabBiomarkersAnti-Allergic Agents

Autor:innen und Institutionen

  • Allergy Department, Allergy Unit, Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND, Malaga, Spain.
  • RICORS de Enfermedades Inflamatorias (ISCIII), Madrid, Spain.
  • Pulmonology Department, Allergy Section, Hospital Clinic and IDIBAPS, Barcelona, Spain.
  • Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.
  • Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain.

ORCID-Profile: C Rondon, M Ferrer, I Eguiluz-Gracia

Förderung

  • Instituto de Salud Carlos III
  • Novartis Pharmaceuticals Corporation
  • Consejería de Salud y Bienestar Social, Junta de Andalucía

Zitieren

APA

Zubiaga-Fernandez, L., Testera-Montes, A., Rondon, C., Perez-Sanchez, N., Gomez-Perez, F., Vega-Chicote, J. M., Bartra, J., Ferrer, M., Eguiluz-Gracia, I., & Torres, M. J. (2024). Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14462

Vancouver

Zubiaga-Fernandez L, Testera-Montes A, Rondon C, Perez-Sanchez N, Gomez-Perez F, Vega-Chicote JM, et al. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14462

BibTeX
@article{ZubiagaFernandez2024,
  author = {Zubiaga-Fernandez, L and Testera-Montes, A and Rondon, C and Perez-Sanchez, N and Gomez-Perez, F and Vega-Chicote, J M and Bartra, J and Ferrer, M and Eguiluz-Gracia, I and Torres, M J},
  title = {Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria},
  journal = {Clinical & Experimental Allergy},
  year = {2024},
  doi = {10.1111/cea.14462}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche